ESMO Congress

The addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone in previously untreated patients with metastatic or unresectable melanoma.

The combination of osimertinib and bevacizumab did not produce a superior progression-free survival benefit vs osimertinib alone in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation.

Fam-trastuzumab deruxtecan-nxki showcased robust and durable antitumor activity in previously treated patients with HER2-mutant non–small cell lung cancer.

Bradley J. Monk, MD, FACS, FACOG, discusses outcomes with pembrolizumab plus chemotherapy in patients with recurrent or metastatic cervical cancer, as reported in the phase 3 KEYNOTE-826 trial.

Cabozantinib as a second-line treatment showed improved overall survival outcomes compared with second-line axitinib in patients with advanced renal cell carcinoma.

Perioperative treatment with cabozantinib induced responses in patients with intermediate and poor-risk metastatic renal cell carcinoma

Filip Janku, MD, PhD, discusses the results form a phase 1 study of ripretinib, a broad-spectrum KIT and PDGFRA inhibitor, in patients with KIT-mutated or KIT-amplified melanoma.

April Rose, MD, discusses the efficacy results of the ongoing phase 2 BEAVER trial in non-V600E BRAF-mutant advanced solid tumors.

Efficacy outcomes were superior with nivolumab plus ipilimumab compared with sunitinib in patients with advanced renal cell carcinoma.

The addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes in patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression.

Combining the PARP inhibitor olaparib with bipolar androgen therapy demonstrated promising clinical activity in patients with castration-resistant prostate cancer.

Rechallenge with maintenance olaparib following response to platinum-based chemotherapy significantly improved progression-free survival in heavily pretreated patients with relapsed ovarian cancer, irrespective of BRCA status, according to results of the phase 3 OReO/ENGOT Ov-38 study.

The frontline combination of nivolumab and ipilimumab continued to demonstrate improved overall survival across subgroups compared with standard chemotherapy at 3 years in patients with unresectable malignant pleural mesothelioma.

Findings from a pair of studies presented at the 2021 European Society for Medical Oncology Annual Meeting showed that adding sintilimab to chemotherapy significantly improved overall survival compared with chemotherapy alone in patients with unresectable, locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma and those with unresectable, locally advanced, recurrent, or metastatic gastric or gastroesophageal junction adenocarcinoma.

Erdafitinib in combination with cetrelimab displayed clinically meaningful responses in patients with metastatic or locally advanced urothelial carcinoma harboring FGFR alterations.

Nivolumab and cabozantinib demonstrated significant benefits in progression-free survival and objective response rate for patients with renal cell carcinoma regardless of whether they had a prior nephrectomy.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus fluoropyrimidine and platinum-containing chemotherapy as frontline treatment for adult patients with HER2-negative advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma with a PD-L1 combined positive score of 5 or higher.

Similarities in clinical characteristics in these patients despite differences in other genomic alterations may impact potential clinical trial treatment selection.

Patients with renal cell carcinoma and their families may have a lack of understanding about the disease, clinical trials, and psychosocial impact.

Brigatinib resulted in a 52% reduction in the risk of disease progression or death and a 56% reduction in the risk of intracranial progression compared with crizotinib in patients with ALK-positive non–small cell lung cancer, according to final data from the phase 3 ALTA-1L trial.

Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts in Japanese patients with non–small cell lung cancer, which, when coupled with pharmacokinetic analysis, led to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in this population.

Mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy when compared indirectly with real-world data of patients treated with standard of care.

Linagliptin plus atezolizumab was linked with limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer who participated in an arm of the open-label, phase 1b/2 MORPHEUS platform.

Patients with endometrial cancer who had a high tumor mutational burden experienced high responses to single-agent dostarlimab-gxly, irrespective of mismatch repair or microsatellite stability status.

The safety profile of daralutamide in combination with androgen-deprivation therapy was similar to placebo in patients with nonmetastatic castration-resistant prostate cancer.

Treatment with darolutamide was associated with statistically significant benefits in episodic memory by computerized cognitive assessment compared with enzalutamide in patients with metastatic castration-resistant prostate cancer.

The 2021 ESMO Congress, held as a virtual format for the second consecutive year, is fast approaching and isn’t holding back in terms of pivotal data across malignancies, especially in breast cancer and gynecologic cancers.

Brigatinib demonstrated sustained improvements in overall and intracranial progression-free survival and health-related quality of life compared with crizotinib in patients with ALK-positive advanced non–small cell lung cancer.

Plinabulin was found to be a more favorable option for the prevention of chemotherapy-induced neutropenia compared with pegfilgrastim during the coronavirus disease 2019 pandemic.

With more than 4 years of follow-up, the health-related quality of life of men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy was shown to be maintained with the addition of apalutamide.